Contribution margins of nursing-home supply in a German community pharmacy: a single-provider costing analysis of medication logistics, multidose blistering and medication review, benchmarked against walk-in dispensing

International Journal of Clinical Pharmacy

Riegel RF, Fehske C, Fiedler A, Kaltenborn A, Schmidt S, Drysch M, Steubing Y, Schöffski O, von Lübken F, Lehnhardt M, Füth M

Corresponding author: Riegel RF, Department of Plastic Surgery, BG University Hospital Bergmannsheil, Bochum, Germany. E-mail: Rouven.Riegel@ruhr-uni-bochum.de

CHEERS 2022 checklist

Manuscript Contribution margins of nursing-home supply in a German community pharmacy: a single-provider costing analysis of medication logistics, multidose blistering and medication review, benchmarked against walk-in dispensing (Riegel RF, Fehske C, Fiedler A, et al.).

Self-assessment 24 reported, 2 not applicable, 2 partially reported (items 16, 18).

#	CHEERS 2022 item and recommendation	Status	Location
1	**Title**: Identify the study as an economic evaluation and specify the interventions being compared.	**Reported**	Title
2	**Abstract**: Provide a structured summary that highlights context, key methods, results, and alternative analyses.	**Reported**	Abstract; Impact of findings on practice
3	**Background and objectives**: Give the context for the study, the study question, and its practical relevance for decision making in policy or practice.	**Reported**	Introduction; Aim
4	**Health economic analysis plan**: Indicate whether a health economic analysis plan was developed and where available.	**Reported**	Method, Design and perspective

5	**Study population**: Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics).	**Reported**	Method, Setting and case selection; Population eligible for review and blister volume
6	**Setting and location**: Provide relevant contextual information that may influence findings.	**Reported**	Method, Design and perspective; Setting and case selection
7	**Comparators**: Describe the interventions or strategies being compared and why chosen.	**Reported**	Method, Outcomes; Scenarios and sensitivity analysis
8	**Perspective**: State the perspective(s) adopted by the study and why chosen.	**Reported**	Method, Design and perspective
9	**Time horizon**: State the time horizon for the study and why appropriate.	**Reported**	Method, Design and perspective
10	**Discount rate**: Report the discount rate(s) and reason chosen.	**Not applicable** (stated)	Method, Design and perspective; One-year horizon; no discounting.
11	**Selection of outcomes**: Describe what outcomes were used as the measure(s) of benefit(s) and harm(s).	**Reported**	Method, Outcomes
12	**Measurement of outcomes**: Describe how outcomes used to capture benefit(s) and harm(s) were measured.	**Reported**	Method, Design and perspective; Outcomes
13	**Valuation of outcomes**: Describe the population and methods used to measure and value outcomes.	**Not applicable** (stated)	Method, Design and perspective; Cost-revenue analysis; no health outcomes valued.
14	**Measurement and valuation of resources and costs**: Describe how costs were valued.	**Reported**	Method, Data sources; Cost and revenue model; Results (Table 2, Footnote)
15	**Currency, price date, and conversion**: Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion.	**Reported**	Method, Design and perspective; Table 1, Method
16	**Rationale and description of model**: If modelling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed.	**Partially reported**	Method, Cost and revenue model; Table 1, Method; reproducible from Table 1 and its footnote
17	**Analytics and assumptions**: Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used.	**Reported**	Method, Cost and revenue model; Population eligible for review; Results (Table 2, Footnote)

18	**Characterizing heterogeneity**: Describe any methods used for estimating how the results of the study vary for subgroups.	**Partially reported**	Method, Population eligible for review; Subgroup analysis not possible
19	**Characterizing distributional effects**: Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations.	**Reported**	Discussion, Distribution of costs and benefits; Discussion, Equity
20	**Characterizing uncertainty**: Describe methods to characterise any sources of uncertainty in the analysis.	**Reported**	Method, Scenarios and sensitivity analysis; Results, Sensitivity; Discussion, Limitations
21	**Approach to engagement with patients and others affected by the study**: Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (such as clinicians or payers) in the design of the study.	**Reported**	Method, Data sources
22	**Study parameters**: Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions.	**Reported**	Table 1, Method; Results
23	**Summary of main results**: Report the mean values for the main categories of costs and outcomes of interest and summarise them in the most appropriate overall measure.	**Reported**	Results; Tables 2–3, Results
24	**Effect of uncertainty**: Describe how uncertainty about analytic judgments, inputs, or projections affect findings. Report the effect of choice of discount rate and time horizon, if applicable.	**Reported**	Results, Sensitivity; Fig. 2, Results; Discussion, Limitations
25	**Effect of engagement with patients and others affected by the study**: Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study.	**Reported**	Method, Data sources
26	**Study findings, limitations, generalisability, and current knowledge**: Report key findings, limitations, ethical or equity considerations not captured, and how these could affect patients, policy, or practice.	**Reported**	Discussion; Conclusion
27	**Source of funding**: Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis.	**Reported**	Statements and Declarations, Funding

28	**Conflicts of interest**: Report authors' conflicts of interest according to journal or International Committee of Medical Journal Editors requirements.	**Reported**	Statements and Declarations, Competing Interests; Author contributions